Syros Pharmaceuticals Merges with TYME Technologies
September 16, 2022
Syros Pharmaceuticals completed a merger with TYME Technologies, acquiring TYME's pipeline assets and approximately $60 million of net cash at closing. The transaction was accompanied by an oversubscribed $130 million PIPE financing to provide capital for Syros' late-stage hematology programs and early commercialization activities.
- Buyers
- Syros Pharmaceuticals, Inc.
- Targets
- TYME Technologies, Inc.
- Industry
- Biotechnology
- Location
- United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Symeres Acquires Oncolines
January 10, 2023
Healthcare Services
Symeres, the Netherlands-headquartered transatlantic CRO & CDMO backed by Keensight Capital, has acquired Oncolines, an Oss-based oncology-focused CRO that provides early biology services and cell-line profiling assays. The add-on expands Symeres' oncology and precision-medicine biology capabilities and brings Oncolines' ~20 employees into the Symeres platform (part of NTRC Holding), increasing the group's integrated drug-discovery offering and proforma revenues to over €100m.
-
Symeres Acquires DGr Pharma
September 15, 2025
Healthcare Services
Symeres has acquired DGr Pharma to strengthen its early‑stage drug development and regulatory consultancy capabilities, accelerating IND‑enabling services for biopharma clients. The deal is supported by Keensight Capital, which backs Symeres and aims to expand the platform's integrated CRDMO offering across discovery and early clinical development.
-
Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare
May 25, 2021
Healthcare Services
Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.
-
Symeres Acquires Exemplify BioPharma
October 25, 2022
Pharmaceuticals
Symeres, a Netherlands-headquartered transatlantic CRO/CDMO majority‑owned by Keensight Capital, has acquired Exemplify BioPharma, a Cranbury, New Jersey-based CMC-focused CRO. The deal strengthens Symeres' capabilities in process and analytical chemistry and formulation development and further expands its strategic foothold in the United States.
-
N-Power Medicine Acquires Syapse
December 30, 2024
Healthcare Services
N-Power Medicine completed a stock-for-stock acquisition of Syapse on December 30, 2024, integrating Syapse’s precision-medicine technology, data assets and network of community oncologists into N-Power’s Kaleido Registry and AI-enabled point-of-care platform. Innovatus Capital Partners joined N-Power’s existing investors (including the Merck Global Health Innovation Fund) to provide ongoing funding; Canaccord Genuity served as Syapse’s exclusive financial advisor.
-
HTEC Acquires SYRMIA
February 13, 2024
IT Services
HTEC has acquired SYRMIA, an embedded software engineering firm based in Belgrade, Serbia, to expand its AI, machine learning, and embedded systems capabilities. The deal strengthens HTEC's engineering footprint in Southeast Europe and provides growth opportunities for the combined team's talent and client offerings.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.